314.18
price up icon0.35%   1.10
after-market After Hours: 291.00 -23.18 -7.38%
loading
Insulet Corporation stock is traded at $314.18, with a volume of 675.13K. It is up +0.35% in the last 24 hours and down -3.34% over the past month. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$313.08
Open:
$312.83
24h Volume:
675.13K
Relative Volume:
0.80
Market Cap:
$21.02B
Revenue:
$2.20B
Net Income/Loss:
$402.20M
P/E Ratio:
56.51
EPS:
5.56
Net Cash Flow:
$280.80M
1W Performance:
+2.12%
1M Performance:
-3.34%
6M Performance:
+20.34%
1Y Performance:
+55.69%
1-Day Range:
Value
$311.78
$316.00
1-Week Range:
Value
$304.13
$316.00
52-Week Range:
Value
$173.00
$329.33

Insulet Corporation Stock (PODD) Company Profile

Name
Name
Insulet Corporation
Name
Phone
978-600-7000
Name
Address
100 NAGOG PARK, ACTON, MA
Name
Employee
3,900
Name
Twitter
@insulet_uk
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PODD's Discussions on Twitter

Compare PODD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
PODD
Insulet Corporation
314.18 21.02B 2.20B 402.20M 280.80M 5.56
Medical Devices icon
ABT
Abbott Laboratories
136.01 233.36B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
107.41 147.06B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
395.63 145.64B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
87.17 112.76B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
78.21 44.46B 5.54B 4.18B 623.10M 7.00

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-16-25 Initiated Truist Buy
May-30-25 Initiated Goldman Buy
May-13-25 Upgrade Wolfe Research Peer Perform → Outperform
Apr-29-25 Downgrade Wolfe Research Outperform → Peer Perform
Mar-06-25 Initiated RBC Capital Mkts Outperform
Nov-06-24 Initiated Bernstein Outperform
May-30-24 Initiated Redburn Atlantic Buy
May-07-24 Upgrade Wolfe Research Peer Perform → Outperform
Dec-21-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-04-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-02-23 Upgrade Jefferies Hold → Buy
Aug-21-23 Upgrade Citigroup Neutral → Buy
Aug-21-23 Downgrade Robert W. Baird Outperform → Neutral
May-30-23 Resumed Morgan Stanley Equal-Weight
Jan-26-23 Initiated Wolfe Research Peer Perform
Nov-04-22 Upgrade Piper Sandler Neutral → Overweight
Oct-18-22 Initiated Barclays Equal Weight
Oct-12-22 Initiated Jefferies Hold
Jul-11-22 Downgrade Citigroup Buy → Neutral
Mar-02-22 Resumed BofA Securities Buy
Feb-03-22 Upgrade BTIG Research Neutral → Buy
Feb-02-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade Oppenheimer Perform → Outperform
Jul-21-21 Resumed Cowen Outperform
May-25-21 Initiated Barclays Overweight
Apr-01-21 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-19-21 Upgrade Canaccord Genuity Hold → Buy
Jan-29-21 Downgrade Piper Sandler Overweight → Neutral
Dec-16-20 Downgrade Citigroup Buy → Neutral
Jul-28-20 Initiated Wells Fargo Overweight
Apr-24-20 Downgrade SVB Leerink Outperform → Mkt Perform
Apr-03-20 Initiated BofA/Merrill Neutral
Mar-31-20 Downgrade Berenberg Buy → Hold
Mar-05-20 Initiated Citigroup Buy
Dec-10-19 Initiated CFRA Sell
Oct-23-19 Initiated Stifel Hold
Oct-18-19 Downgrade Canaccord Genuity Buy → Hold
Oct-14-19 Downgrade BTIG Research Buy → Neutral
Oct-04-19 Downgrade UBS Buy → Neutral
Oct-03-19 Downgrade Guggenheim Buy → Neutral
Aug-06-19 Upgrade JP Morgan Neutral → Overweight
Jun-10-19 Downgrade Northland Capital Outperform → Market Perform
May-06-19 Upgrade BTIG Research Neutral → Buy
Apr-20-18 Initiated Berenberg Buy
Feb-22-18 Reiterated Barclays Overweight
Jan-08-18 Upgrade Raymond James Mkt Perform → Outperform
Nov-03-17 Upgrade Canaccord Genuity Hold → Buy
Sep-15-17 Initiated Barclays Overweight
View All

Insulet Corporation Stock (PODD) Latest News

pulisher
Jun 17, 2025

Truist bullish on diabetes companies citing potential market growth - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Insulet’s SWOT analysis: patch pump leader’s stock poised for growth By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Insulet’s SWOT analysis: patch pump leader’s stock poised for growth - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

Analyst Predicts Strong Growth for Insulet (PODD) with Buy Ratin - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Insider Sell: Dan Manea Sells 1,300 Shares of Insulet Corp (PODD) - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Insulet, EyePoint & NanoDx receive $2M in tax incentives to create life sciences jobs - Worcester Business Journal

Jun 16, 2025
pulisher
Jun 16, 2025

Insulet (PODD) Rated 'Buy' by Truist Securities; Price Target Set at $365 | PODD Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

(PODD) Investment Report - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Truist initiates Insulet stock with buy rating on diabetes pump potential - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Initiates Insulet at Buy With $365 Price Target - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Securities Starts Insulet Corporation (PODD) at Buy - StreetInsider

Jun 16, 2025
pulisher
Jun 13, 2025

Insulet’s SWOT analysis: pump maker’s stock rides wave of growth By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Insulet’s SWOT analysis: pump maker’s stock rides wave of growth - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Here's Why You Should Retain PODD Stock in Your Portfolio Now - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

Insulet Boosts Its Diabetes Device Via Comical Campaign -- And A Comic Book 06/12/2025 - MediaPost

Jun 11, 2025
pulisher
Jun 11, 2025

Marvel’s latest superhero: Insulet’s comic book star with type 1 diabetes - Medical Marketing and Media

Jun 11, 2025
pulisher
Jun 11, 2025

Insulet, Marvel collab to unveil comic book hero with type 1 diabetes - MassDevice

Jun 11, 2025
pulisher
Jun 11, 2025

Possible Bearish Signals With Insulet Insiders Disposing Stock - simplywall.st

Jun 11, 2025
pulisher
Jun 10, 2025

Insulet Director Cashes In on Stock Sale! - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Insider Sell: Luciana Borio Sells Shares of Insulet Corp (PODD) - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet at Goldman Sachs Conference: Strategic Growth and Leadership Transition - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Transcript : Insulet Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration N - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet announces Omnipod 5 App for iPhone is compatible with Dexcom G7 CGM - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet To Present At Goldman Sachs Global Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption - Yahoo Finance

Jun 10, 2025
pulisher
Jun 09, 2025

Insulet Corporation (PODD) Announces Credit Agreement Refinancin - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Insulet Corporation (PODD) Announces Credit Agreement Refinancing and Convertible Notes Redemption - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Insulet Issues Redemption Notice for Convertible Notes - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Insulet enters eighth amendment to credit agreementSEC filing - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

3 Medical Technology Stocks Outperforming in 2025 - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

Raindrop Injects Personality Into Omnipod 5’s Diabetes Campaign - Little Black Book | LBBOnline

Jun 09, 2025
pulisher
Jun 08, 2025

Omnipod 5 Helps Make Diabetes a Smaller Part of Life In New Work From Raindrop - citybiz

Jun 08, 2025
pulisher
Jun 05, 2025

TD Cowen Raises Insulet (PODD) Price Target, Maintains Buy Rating - Insider Monkey

Jun 05, 2025
pulisher
Jun 05, 2025

TD Cowen raises Insulet stock price target to $379 after strong Q1 - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 04, 2025

Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Goldman Sachs Initiates Coverage of Insulet (PODD) with Buy Rating - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

TD Cowen raises Insulet stock price target to $379 after strong Q1 By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Insulet Corporation (PODD) PT Raised to $379 at TD Cowen After a Stellar 1Q - StreetInsider

Jun 04, 2025
pulisher
Jun 04, 2025

TD Cowen Boosts Insulet (PODD) Price Target Following Strong Quarter | PODD Stock News - GuruFocus

Jun 04, 2025

Insulet Corporation Stock (PODD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Insulet Corporation Stock (PODD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Singh Prem
SVP, Global Operations
Jun 13 '25
Sale
300.05
2,327
698,216
4,143
Manea Dan
SVP, Chief HR Officer
Jun 13 '25
Sale
300.05
1,300
390,065
9,090
medical_devices PHG
$23.98
price down icon 0.66%
medical_devices STE
$240.22
price up icon 0.60%
$87.29
price up icon 1.11%
$74.07
price down icon 0.42%
medical_devices EW
$78.21
price up icon 0.00%
Cap:     |  Volume (24h):